HRP20000502B1 - NOVI KRISTALINIČNI OBLIK 6-HIDROKSI-3-(4-[2-(PIPERIDIN-1-IL)ETOKSI]FENOKSI)-2-(4-METOKSIFENIL)BENZO[b]TIOFEN HIDROKLORIDA - Google Patents

NOVI KRISTALINIČNI OBLIK 6-HIDROKSI-3-(4-[2-(PIPERIDIN-1-IL)ETOKSI]FENOKSI)-2-(4-METOKSIFENIL)BENZO[b]TIOFEN HIDROKLORIDA

Info

Publication number
HRP20000502B1
HRP20000502B1 HR20000502A HRP20000502A HRP20000502B1 HR P20000502 B1 HRP20000502 B1 HR P20000502B1 HR 20000502 A HR20000502 A HR 20000502A HR P20000502 A HRP20000502 A HR P20000502A HR P20000502 B1 HRP20000502 B1 HR P20000502B1
Authority
HR
Croatia
Prior art keywords
piperidin
benzo
methoxyphenyl
phenoxy
ethoxy
Prior art date
Application number
HR20000502A
Other languages
English (en)
Inventor
Kay Bush Julie
Charles Conrad Preston
Gerard Flom Merlyn
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20000502A2 publication Critical patent/HRP20000502A2/hr
Publication of HRP20000502B1 publication Critical patent/HRP20000502B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)

Abstract

Kristalinični 6-hidroksi-3-(4-[2-(piperidin-1-il)etoksi]fenoksi)-2-(4-metoksifenil)benzo[b]tiofen-hidroklorid hidrat (F-III), naznačen time što mu uzorak difrakcije rendgenskih zraka sadrži sljedeće reflekse: 4,6 ± 0,2; 7,8 ± 0,2; 9,3 ± 0,2; 14,0 ± 0,2; 17,6 ± 0,2; 20,8 ± 0,2 i 24,3 ± 0,2° u 2θ; dobivene na 25 ± 2 °C i 35 ± 10 % relativne vlage iz bakrenog izvora zračenja (CuK?; λ = 1,54056 A). Patent sadrži još 4 patentna zahtjeva.
HR20000502A 1999-07-29 2000-07-25 NOVI KRISTALINIČNI OBLIK 6-HIDROKSI-3-(4-[2-(PIPERIDIN-1-IL)ETOKSI]FENOKSI)-2-(4-METOKSIFENIL)BENZO[b]TIOFEN HIDROKLORIDA HRP20000502B1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14618499P 1999-07-29 1999-07-29
US14764299P 1999-08-06 1999-08-06
US14982099P 1999-08-19 1999-08-19

Publications (2)

Publication Number Publication Date
HRP20000502A2 HRP20000502A2 (en) 2001-06-30
HRP20000502B1 true HRP20000502B1 (hr) 2008-04-30

Family

ID=27386367

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000502A HRP20000502B1 (hr) 1999-07-29 2000-07-25 NOVI KRISTALINIČNI OBLIK 6-HIDROKSI-3-(4-[2-(PIPERIDIN-1-IL)ETOKSI]FENOKSI)-2-(4-METOKSIFENIL)BENZO[b]TIOFEN HIDROKLORIDA

Country Status (45)

Country Link
EP (1) EP1204655B1 (hr)
JP (1) JP2001048880A (hr)
KR (1) KR100733094B1 (hr)
CN (1) CN1138771C (hr)
AR (1) AR029176A1 (hr)
AT (2) ATE251151T1 (hr)
AU (2) AU6335500A (hr)
BE (1) BE1013410A3 (hr)
BR (1) BR0003211A (hr)
CA (1) CA2314685C (hr)
CO (1) CO5180572A1 (hr)
CZ (1) CZ300356B6 (hr)
DE (2) DE60005693T2 (hr)
DK (1) DK176771B1 (hr)
EG (1) EG24196A (hr)
ES (1) ES2208384T3 (hr)
FI (1) FI20001721A (hr)
FR (1) FR2798384B1 (hr)
GB (1) GB2352716A (hr)
GR (1) GR20000100264A (hr)
HK (1) HK1034962A1 (hr)
HR (1) HRP20000502B1 (hr)
HU (1) HUP0003005A2 (hr)
ID (1) ID26679A (hr)
IL (1) IL137552A (hr)
IT (1) IT1318659B1 (hr)
LT (1) LT4789B (hr)
LU (1) LU90616B1 (hr)
LV (1) LV12733B (hr)
MD (1) MD2335G2 (hr)
MX (1) MXPA00007462A (hr)
MY (1) MY120393A (hr)
NL (1) NL1015822C2 (hr)
NO (1) NO325594B1 (hr)
NZ (1) NZ506045A (hr)
PE (1) PE20010383A1 (hr)
PL (1) PL341748A1 (hr)
PT (1) PT102501A (hr)
SE (1) SE0002793L (hr)
SG (1) SG90737A1 (hr)
SI (1) SI20427B (hr)
SV (1) SV2002000134A (hr)
TR (1) TR200002205A2 (hr)
TW (1) TWI271403B (hr)
WO (1) WO2001009115A2 (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122203B2 (en) 2000-05-08 2006-10-17 Eli Lilly And Company Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
SK286346B6 (en) * 2000-05-08 2008-07-07 Lilly Co Eli Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
AU2005200809B2 (en) * 2000-05-08 2006-05-11 Eli Lilly And Company Stabilized Formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) Ethoxy]phenoxy)-2-(4-methoxyphenyl) Benzo[b]thiophene and Salts Thereof
EP1757291A3 (en) * 2000-05-08 2009-07-15 Eli Lilly & Company Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
CN1268624C (zh) * 2000-10-20 2006-08-09 伊莱利利公司 6－羟基－3－(4－[2－(哌啶－1－基)乙氧基]苯氧基)－2－(4－甲氧基苯基)苯并[b]噻吩盐酸盐的新晶形
US6921827B2 (en) 2000-11-27 2005-07-26 Eli Lilly And Company Process for preparing 3-aryl-benzo{b} thiophenes
ATE480534T1 (de) * 2004-07-22 2010-09-15 Lilly Co Eli Kristallines variables hydrat von (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxy ropyl)amino)-2- methylpropyl)phenoxy)-3-pyridincarbonsäureamid- hemisuccinatsalz
EP2425846A1 (en) * 2004-12-23 2012-03-07 Voyager Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
WO2006088648A1 (en) * 2005-02-11 2006-08-24 Eli Lilly And Company Compositions and methods for treating dyslipidemia
DE102008057230A1 (de) * 2008-11-11 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin
CN113325183B (zh) * 2021-06-01 2022-11-15 中国医学科学院北京协和医院 一种用于鉴别诊断em/fem的试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
PL182493B1 (pl) * 1995-02-28 2002-01-31 Lilly Co Eli Nowe pochodne benzotiofenu, nowe związki pośrednie i sposób wytwarzania nowych pochodnych benzotiofenu oraz środek farmaceutyczny
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
AU6335600A (en) * 1999-07-29 2001-02-19 Eli Lilly And Company A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride

Also Published As

Publication number Publication date
CN1283622A (zh) 2001-02-14
AU4891100A (en) 2001-02-01
ES2208384T3 (es) 2004-06-16
EP1204655B1 (en) 2003-10-01
CN1138771C (zh) 2004-02-18
SG90737A1 (en) 2002-08-20
CO5180572A1 (es) 2002-07-30
ITMI20001758A1 (it) 2002-01-28
KR100733094B1 (ko) 2007-06-27
GR20000100264A (el) 2001-03-30
SI20427B (sl) 2009-04-30
TWI271403B (en) 2007-01-21
PL341748A1 (en) 2001-02-12
TR200002205A2 (tr) 2001-03-21
EP1204655A2 (en) 2002-05-15
AR029176A1 (es) 2003-06-18
NL1015822C2 (nl) 2004-08-04
MD20000161A (en) 2001-04-30
KR20010049911A (ko) 2001-06-15
WO2001009115A3 (en) 2001-08-16
HUP0003005A2 (hu) 2002-04-29
IT1318659B1 (it) 2003-08-27
MD2335F2 (en) 2003-12-31
DE60005693T2 (de) 2004-07-29
HK1034962A1 (en) 2001-11-09
GB2352716A (en) 2001-02-07
ATE251151T1 (de) 2003-10-15
NZ506045A (en) 2002-02-01
ID26679A (id) 2001-02-01
IL137552A0 (en) 2001-07-24
FI20001721A (fi) 2001-01-30
MXPA00007462A (es) 2002-06-04
HU0003005D0 (en) 2000-10-28
MD2335G2 (ro) 2004-06-30
CZ20002717A3 (en) 2001-05-16
CA2314685A1 (en) 2001-01-29
WO2001009115A2 (en) 2001-02-08
FR2798384B1 (fr) 2004-09-24
SV2002000134A (es) 2002-06-07
EG24196A (en) 2008-10-14
PT102501A (pt) 2001-01-31
BR0003211A (pt) 2001-03-13
MY120393A (en) 2005-10-31
GB0018636D0 (en) 2000-09-13
DK200001150A (da) 2001-01-30
IL137552A (en) 2009-06-15
PE20010383A1 (es) 2001-04-05
NL1015822A1 (nl) 2001-01-30
ITMI20001758A0 (it) 2000-07-28
LT4789B (lt) 2001-05-25
DK176771B1 (da) 2009-08-03
JP2001048880A (ja) 2001-02-20
LT2000075A (lt) 2001-02-26
SE0002793L (sv) 2001-01-30
NO20003876D0 (no) 2000-07-28
CZ300356B6 (cs) 2009-04-29
LV12733B (lv) 2002-02-20
FR2798384A1 (fr) 2001-03-16
DE10036855A1 (de) 2001-03-22
FI20001721A0 (fi) 2000-07-28
AU6335500A (en) 2001-02-19
SI20427A (sl) 2001-06-30
AU779559B2 (en) 2005-01-27
HRP20000502A2 (en) 2001-06-30
BE1013410A3 (fr) 2001-12-04
DE60005693D1 (de) 2003-11-06
CA2314685C (en) 2009-10-20
NO20003876L (no) 2001-01-30
AT502317A1 (de) 2007-02-15
SE0002793D0 (sv) 2000-07-28
IE20000604A1 (en) 2001-04-04
LV12733A (lv) 2001-10-20
LU90616B1 (fr) 2007-06-08
NO325594B1 (no) 2008-06-23

Similar Documents

Publication Publication Date Title
HRP20000502B1 (hr) NOVI KRISTALINIČNI OBLIK 6-HIDROKSI-3-(4-[2-(PIPERIDIN-1-IL)ETOKSI]FENOKSI)-2-(4-METOKSIFENIL)BENZO[b]TIOFEN HIDROKLORIDA
HRP20000503B1 (hr) NOVI KRISTALINIČNI OBLIK 6-HIDROKSI-3-(4-[2-(PIPERIDIN-1-IL)ETOKSI]FENOKSI)-2-(4-METOKSIFENIL)BENZO[b]TIOFEN HIDROKLORIDA
MXPA03003432A (es) Nueva forma cristalina de clorhidrato de 6-hidroxi -3-(4 -(2 -(piperidin-1- il)etoxi)fenoxi) -2-(4-metoxifenil) benzo (b) tiofeno.
HUP9904035A3 (en) Modified crystalline form of the r-(-)-n-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
CY2344B1 (en) A novel crystalline form of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy) phenoxy)-2-(4-methoxyphenyl) benzo (b) thiphene hydrochloride.
ZA200003838B (en) A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride.
TJ399B (en) A novel crystalline form of 6-hydroxy -3-(4-Ä2-(piperidin-1-yl) ethoxyÜ- phenoxy) -2-(4-methoxyphenyl) benzo ÄBÜ thiophene hydrochloride.
TJ398B (en) A novel crystalline form of 6-hydroxy -3-(4-Ä2-(piperidin-1-yl) ethoxyÜ-phenoxy) -2-(4-methoxyphenyl) benzo ÄbÜ thiophene hydrochloride.
HUP0302190A3 (en) Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
ECSP003592A (es) UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6- HIDROXI- 3-(4-[2-(PIPERIDIN-1-IL) ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO [b]TIOFENO
ECSP003593A (es) UNA NUEVA FORMA CRISTALINA DE CLORHIDRATO DE 6- HIDROXI- 3-(4-[2-(PIPERIDIN-1-IL) ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO [b]TIOFENO

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20090629

Year of fee payment: 10

PBON Lapse due to non-payment of renewal fee

Effective date: 20100726